Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies.
Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies.
复制标题
DOI：
10.1586/ecp.09.62
复制
发表时间：
2010-03-01
影响因子：
4.4
通讯作者：
Storr, Martin
中科院分区：
文献类型：
--
作者：
Schicho, Rudolf;Storr, Martin
从大麻植物（Cannabis sativa）中提取的大麻素和合成大麻素对胃肠道（GI）功能有许多影响。最近的实验数据支持大麻素在胃肠道疾病中的重要作用。人类遗传学研究已经证明，内源性大麻素代谢缺陷是功能性胃肠道疾病的基础。哺乳动物细胞具有所谓的内源性大麻素系统（ECS）的机制，以产生和代谢它们自己的大麻素，从而以快速适应的方式控制肠道的稳态。通过大麻素或通过提高内源性大麻素水平的药物对ECS进行药理学操作，已经显示出对GI病理生理学的有益作用。本文综述了ECS在胃肠道中的功能，突出了ECS在胃肠道疾病中的作用，并讨论了其潜在的药理学开发。
Cannabinoids extracted from the marijuana plant (Cannabis sativa) and synthetic cannabinoids have numerous effects on gastrointestinal (GI) functions. Recent experimental data support an important role for cannabinoids in GI diseases. Genetic studies in humans have proven that defects in endocannabinoid metabolism underlie functional GI disorders. Mammalian cells have machinery, the so-called endocannabinoid system (ECS), to produce and metabolize their own cannabinoids in order to control homeostasis of the gut in a rapidly adapting manner. Pharmacological manipulation of the ECS by cannabinoids, or by drugs that raise the levels of endogenous cannabinoids, have shown beneficial effects on GI pathophysiology. This review gives an introduction into the functions of the ECS in the GI tract, highlights the role of the ECS in GI diseases and addresses its potential pharmacological exploitation.